Jump Financial’s INmune Bio INMB Stock Holding History

Jump Financial’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-21,100	Closed	-$215K	–	1708
2021 Q4	$215K	Buy	+21,100	New	+$312K	0.01%	1072

Other funds holding INMB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $127M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Jump Financial's INMB Position: Q1 2022 in Review

Jump Financial sold out of INmune Bio (INMB) in Q1 2022, closing a stake of 21,100 shares — an estimated $215K sold.

Jump Financial first reported a position in INMB in Q4 2021 and held it in 1 quarter. The position peaked at $215K in Q4 2021. 34 funds tracked by Wall St. Rank hold INMB as of Q1 2022.

Jump Financial reported no remaining INmune Bio position as of Q1 2022 after selling out during the quarter.
Jump Financial sold 21,100 INmune Bio shares in Q1 2022, an estimated $215K.
Jump Financial first reported a position in INmune Bio in Q4 2021 and held it in 1 quarter.
Jump Financial's INmune Bio position peaked at $215K in Q4 2021.
34 funds tracked by Wall St. Rank held INmune Bio as of Q1 2022.

Based on Jump Financial's 13F filing for Q1 2022, filed 12 May 2022.